Table 3

Association of the level of promoter methylation with clinicopathologic charactristics of NSCLC

Genes

Gender (n = 96)

Histologic type (n = 96)

Smoking history (n = 96)

Female

Male

P

SCC

ADC

P

Y

N

P

(n = 30)

(n = 66)

(n = 66)

(n = 30)

(n = 66)

(n = 30)

CALCA

145.0 ± 149.6

112.1 ± 106.5

0.28

152.1 ± 152.1

96.4 ± 90.6

0.07

155.2 ± 150.2

89.6 ± 92.7

0.03*

CDH1

33.1 ± 18.7

31.5 ± 21.2

0.71

35.4 ± 19.2

26.3 ± 18.6

0.03*

32.2 ± 18.7

33.4 ± 21.3

0.77

DAPK1

18.5 ± 59.6

23 ± 45.2

0.71

26.2 ± 65.8

5.9 ± 7.6

0.09

17.4 ± 59.6

25.4 ± 45.2

0.52

IRX2

96.4 ± 131.5

63.9 ± 34.8

0.19

92.3 ± 115.7

72.9 ± 103.6

0.43

95.3 ± 132.1

66.3 ± 36.1

0.24

TIMP3

60.5 ± 72.8

50.9 ± 39.1

0.50

64.9 ± 71.7

41.3 ± 39.8

0.09

61.5 ± 72.8

48.8 ± 38.9

0.37

PAX6

23.4 ± 15.1

24.2 ± 13.8

0.78

24.0 ± 15.5

23.1 ± 12.8

0.79

23.9 ± 15.6

23.3 ± 12.6

0.85

Genes

Lymph node metastasis (n = 96)

Pleural indentation (n = 96)

Invasion or Adhesion (n = 96)

Y

N

P

Y

N

P

Y

N

P

(n = 26)

(n = 70)

(n = 21)

(n = 75)

(n = 31)

(n = 65)

CALCA

175.7 ± 175.1

119.5 ± 119.1

0.08

129.9 ± 132.5

136 ± 140.2

0.86

174.5 ± 160

115.1 ± 122.5

0.048*

CDH1

31.0 ± 13.9

33.1 ± 21.2

0.64

35.3 ± 21.2

31.8 ± 18.9

0.47

30.7 ± 16.6

33.5 ± 20.7

0.52

DAPK1

40.3 ± 100.5

12.3 ± 18.5

0.03*

12.4 ± 11.9

21.9 ± 62.3

0.49

10.9 ± 10.6

24.2 ± 66.6

0.27

IRX2

42.7 ± 51

91.2 ± 127.2

0.47

73.1 ± 38.4

89.9 ± 124.9

0.54

71.8 ± 48.3

93.1 ± 131.6

0.38

TIMP3

69.3 ± 91

53.2 ± 51

0.28

53.9 ± 42.9

58.6 ± 69.2

0.77

52.7 ± 53.1

59.8 ± 69.1

0.61

PAX6

23.2 ± 14.2

23.9 ± 14.9

0.83

25.2 ± 13.9

23.3 ± 14.9

0.59

25.8 ± 15.7

22.7 ± 14.1

0.32

Ji et al. Diagnostic Pathology 2011 6:48   doi:10.1186/1746-1596-6-48